{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:07:53Z","timestamp":1789016873167,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.clml.2012.12.003","type":"journal-article","created":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T22:45:35Z","timestamp":1357771535000},"page":"296-301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Feasibility of Allografting in Patients with Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab Ozogamicin"],"prefix":"10.1016","volume":"13","author":[{"given":"Partow","family":"Kebriaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaci","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Worth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2012.12.003_bib1","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2012.12.003_bib2","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.12.003_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.blre.2011.08.001","article-title":"Chemoimmunotherapy in acute lymphoblastic leukemia","volume":"26","author":"Hoelzer","year":"2012","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2012.12.003_bib4","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.12.003_bib5","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1517\/14656566.2012.672974","article-title":"Tyrosine kinase inhibitors in acute and chronic leukemias","volume":"13","author":"Ohanian","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clml.2012.12.003_bib6","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","article-title":"First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.12.003_bib7","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.12.003_bib8","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0889-8588(05)70188-X","article-title":"Treatment of adult ALL according to protocols of the German Multicenter Study Group for adult ALL (GMALL)","volume":"14","author":"Gokbuget","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2012.12.003_bib9","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern therapy of acute lymphoblastic leukemia","volume":"29","author":"Bassan","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.12.003_bib10","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cncr.24862","article-title":"Adult acute lymphoblastic leukemia: concepts and strategies","volume":"116","author":"Faderl","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2012.12.003_bib11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1053\/j.seminhematol.2008.09.003","article-title":"Treatment of adult acute lymphoblastic leukemia","volume":"46","author":"G\u00f6kbuget","year":"2009","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2012.12.003_bib12","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group pilot study","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.12.003_bib13","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.12.003_bib14","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.12.003_bib15","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3324\/haematol.2011.057851","article-title":"High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003-2007","volume":"97","author":"Kozlowski","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2012.12.003_bib16","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","article-title":"Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial","volume":"21","author":"Tavernier","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2012.12.003_bib17","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.2174\/1381612003398564","article-title":"Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research","volume":"6","author":"Thorson","year":"2000","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.clml.2012.12.003_bib18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2012.12.003_bib19","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.bbmt.2011.08.011","article-title":"Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes","volume":"18","author":"Kebriaei","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2012.12.003_bib20","first-page":"825","article-title":"Consensus Conference on Acute GVHD Grading","volume":"1995","author":"Przepiorka","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2012.12.003_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2002-23204","article-title":"Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease)","volume":"22","author":"DeLeve","year":"2002","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.clml.2012.12.003_bib22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Amer Statist Assn"},{"key":"10.1016\/j.clml.2012.12.003_bib23","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O","article-title":"Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy","volume":"86","author":"Thomas","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2012.12.003_bib24","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.exphem.2012.04.004","article-title":"How can we reduce hepatic veno-occlusive disease-related deaths after allogeneic stem cell transplantation?","volume":"40","author":"Johnson","year":"2012","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2012.12.003_bib25","first-page":"3599","article-title":"Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation","volume":"92","author":"Carreras","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.12.003_bib26","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/0360-3016(88)90009-0","article-title":"Venocclusive disease of the liver after allogeneic bone marrow transplantation in man","volume":"14","author":"Ganem","year":"1988","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2012.12.003_bib27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S1083-8791(99)70006-6","article-title":"Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome","volume":"5","author":"Lee","year":"1999","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2012.12.003_bib28","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.bmt.1705425","article-title":"Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia","volume":"38","author":"Kebriaei","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2012.12.003_bib29","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.bbmt.2012.06.010","article-title":"Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation","volume":"18","author":"Kebriaei","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2012.12.003_bib30","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.12.003_bib31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","article-title":"Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project","volume":"31","author":"McKoy","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2012.12.003_bib32","doi-asserted-by":"crossref","first-page":"975","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00002","article-title":"Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation","volume":"128","author":"Essell","year":"1998","journal-title":"Ann Intern Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012002893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012002893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:30Z","timestamp":1761870270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265012002893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S2152265012002893"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2012.12.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility of Allografting in Patients with Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab Ozogamicin","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2012.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}